NCT05255458 - A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

November 4, 2021

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions

Hyperlipidemia

Interventions

BIOLOGICAL

AK102

Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies

DRUG

Placebo

Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies

Trial Locations (1)

The Third Hospital of Nanchang, Nanchang